High glucose levels abolish antiatherosclerotic benefits of ACE inhibition in alloxan-induced diabetes in rabbits

High glucose levels abolish antiatherosclerotic benefits of ACE inhibition in alloxan-induced diabetes in rabbits

Autor Pomaro, D. R. Google Scholar
Ihara, SSM Google Scholar
Pinto, Leonor do Espírito Santo de Almeida Autor UNIFESP Google Scholar
Ueda, Ivete Autor UNIFESP Google Scholar
Casarini, Dulce E. Autor UNIFESP Google Scholar
Ebihara, Fabiana Autor UNIFESP Google Scholar
Santos, Andreza O. Autor UNIFESP Google Scholar
Izar, Maria Cristina de Oliveira Autor UNIFESP Google Scholar
Fonseca, Francisco Antonio Helfenstein Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Renin-angiotensin system activation is recognized to play an important role in atherosclerosis. This study aimed to verify the antiatherosclerotic effects of ACE inhibition on an experimental model of diabetes and hypercholesterolemia. Diabetes was induced in New Zealand male rabbits with a single dose of alloxan (100 mg/kg, IV), and, according to plasma glucose levels obtained after 1 week, the animals were divided into 2 groups (>= 250 mg/dL or < 250 mg/dL). Each group was randomly assigned to receive or not quinapril (30 mg/d) added to a 0.5% cholesterol-enriched diet. Animals with high glucose levels at 1 week and that remained high after 12 weeks presented higher triglyceride levels (P < 0.02 versus basal). Those initially hyperglycemic but presenting < 250 mg/dL glucose at the end of study formed an additional group. Plasma ACE activity was lower in quinapril-treated animals (P < 0.01 versus untreated groups). However, aorta intima/media ratio and intima area were lower only in the subgroups of quinapril-treated animals with low glucose levels (P < 0.05). Our results support the hypothesis that high plasma glucose may abolish the anti atheroscl erotic effect of ACE inhibitors.
Palavra-chave ACE inhibitor
atherosclerosis
diabetes
cholesterol
rabbits
Idioma Inglês
Data de publicação 2005-04-01
Publicado em Journal of Cardiovascular Pharmacology. Philadelphia: Lippincott Williams & Wilkins, v. 45, n. 4, p. 295-300, 2005.
ISSN 0160-2446 (Sherpa/Romeo, fator de impacto)
Publicador Lippincott Williams & Wilkins
Extensão 295-300
Fonte http://dx.doi.org/10.1097/01.fjc.0000155384.64350.45
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000227939100004
Endereço permanente http://repositorio.unifesp.br/handle/11600/28200

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta